Japanese molecular biologists have developed a special paint, which gives
API expands health data into risk scores, but are consumers ready for it?
Source: Read Full Article
Positive Barhemsys Phase 3 Treatment Data Published in Anesthesia & Analgesia
Cambridge, UK and Indianapolis, US – 14 September 2018: Acacia
Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of Yupelri (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018 /PRNewswire/